- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 23.01. | Novo climbs higher on 'strong' Wegovy pill launch; Terns tweaks leukemia drug deal | ||
| 23.01. | Congress eyes tackling healthcare consolidation | ||
| 22.01. | Investors load Corxel with $287M for a 'differentiated' obesity pill | ||
| 22.01. | Bristol Myers buys into Janux's 'masked' T cell engagers | ||
| 22.01. | FDA lays out new path to speed development of multiple myeloma drugs | ||
| 22.01. | BioMarin vets form Mendra to 'modernize' rare disease drug development | ||
| 21.01. | Corvus shares nearly triple on positive data for eczema pill | ||
| 21.01. | J&J eyes $100B in sales amid gains for cancer, immune drugs | ||
| 21.01. | Moderna cancer vaccine holds up; IO Biotech considers a sale | ||
| 20.01. | Valneva to withdraw Chikungunya vaccine from US amid safety woes | ||
| 20.01. | GSK to buy Rapt in $2.2B deal for food allergy drug | ||
| 20.01. | Kailera's Ron Renaud on how a China-linked startup can compete in obesity | ||
| 20.01. | When every day counts: Building CRO partnerships on a foundation of trust, care and precision | ||
| 20.01. | The patient retention crisis is happening before enrollment even begins | ||
| 16.01. | Wegovy pill off to a fast start; Ex-Emergent CEO sued for insider trading | ||
| 16.01. | On biotech's biggest stage, renewed excitement gets a stress test | ||
| 15.01. | Trump unveils healthcare affordability plan | ||
| 15.01. | Tecvayli tops standard drugs in early multiple myeloma, J&J says | ||
| 15.01. | Oxford Biomedica confirms takeover talks with biotech investor EQT | ||
| 15.01. | Boston Scientific to acquire Penumbra for $14.5B | ||
| 14.01. | JPM26: Paying cash for obesity drugs, renewed IPO optimism and pharma's cell therapy view | ||
| 14.01. | Lilly, chasing Novo, expects second-quarter FDA decision on obesity pill | ||
| 14.01. | Caldera starts up with $112.5M and a dual-targeting immune drug from China | ||
| 13.01. | JPM26: Biotech's M&A lift, the 'new' Biogen and Merck's $70B target | ||
| 13.01. | Digital health funding increases in 2025, spurred by AI: report |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.